Taken together, our results demonstrate that S100A9 is an efficient tool to target immune niches in different tissues to improve ID-induced metabolic derangements (hyperglycemia via the immune cells in the muscle, and hypertriglyceridemia and hyperketonemia via KCs in the liver) by TLR4-dependent mechanism(s). Here, S100A9 is linked to hypertriglyceridemia.